
Andres F. Diaz
Lead Developer, Molecular Biology Specialist | MD/PhD Candidate, University of Arizona COM, Tuscon
Team
- Andres Diaz (above)
- Thomas Larsen, PhD (University of Arizona College of Medicine – Tucson)
Prototype Development Lead, Biomedical Engineer Advisor - Anish Vaddireddy, BS (Deloitte, New York, NY)
Data Scientist Lead, App Development - Sohail Daulat, BS (University of Pittsburgh, Pittsburgh, PA)
Marketing & Biotech Lead, Second App Developer
Summary | EzMTX
High-dose methotrexate (HDMTX) is a key treatment for pediatric malignancies. However, in low-resource settings, clinicians face challenges due to the lack of accessible MTX monitoring tools, making it difficult to track toxicities and optimize treatment. To address this, we designed a low-cost, portable assay for urine-based MTX monitoring: the EzMTX assay. We leverage MTX’s inhibition of dihydrofolate reductase to produce a simple, clinically relevant readout, then integrate this with a digital app that quantifies results for clinical use. Our assay empowers safer and effective HDMTX treatment and supports equitable global pediatric cancer care.
Back to the Innovation Festival